The treatment target for patients with giant cell arteritis or polymyalgia rheumatica should be remission, with vascular damage prevention taking priority in patients with GCA, according to treat-to-target recommendations from EULAR.
“Treatment targets have already been defined in several areas of rheumatology, including rheumatoid arthritis (RA), spondyloarthritis (SpA), gout and systemic lupus erythematosus (SLE),” Christian Dejaco, MD, of the division of rheumatology and clinical immunology at Medical University of Graz, in Austria, and colleagues wrote in the Annals of the